Literature DB >> 27513184

Preferential Cancer Cell Self-Recognition and Tumor Self-Targeting by Coating Nanoparticles with Homotypic Cancer Cell Membranes.

Jing-Yi Zhu1, Di-Wei Zheng1, Ming-Kang Zhang1, Wu-Yang Yu1, Wen-Xiu Qiu1, Jing-Jing Hu1, Jun Feng1, Xian-Zheng Zhang1.   

Abstract

The ultimate goal in cancer therapy and diagnosis is to achieve highly specific targeting to cancer cells. Coated with the source cancer cell membrane specifically derived from the homologous tumors, the nanoparticles are identified with the self-recognition internalization by the source cancer cell lines in vitro and the highly tumor-selective targeting "homing" to the homologous tumor in vivo even in the competition of another heterologous tumor. As the result, MNP@DOX@CCCM nanovehicle showed strong potency for tumor treatment in vivo and the MR imaging. This bioinspired strategy shows great potential for precise therapy/diagnosis of various tumors merely by adjusting the cell membrane source accordingly on the nanoparticle surface.

Entities:  

Keywords:  MRI; Tumor self-targeting (TST); cancer cell membrane; cancer cell self-recognition; magnetic iron oxide

Mesh:

Substances:

Year:  2016        PMID: 27513184     DOI: 10.1021/acs.nanolett.6b02786

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  79 in total

1.  Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.

Authors:  Flavia Fontana; Raquél Bartolo; Hélder A Santos
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Engineering biological interactions on the nanoscale.

Authors:  Yao Jiang; Sanam Chekuri; Ronnie H Fang; Liangfang Zhang
Journal:  Curr Opin Biotechnol       Date:  2018-11-01       Impact factor: 9.740

3.  Cell membrane-coated gold nanoparticles for apoptosis imaging in living cells based on fluorescent determination.

Authors:  Xiaojun Hu; Hongjie Li; Xing Huang; Zhikang Zhu; Han Zhu; Yao Gao; Zhongzheng Zhu; Hongxia Chen
Journal:  Mikrochim Acta       Date:  2020-02-18       Impact factor: 5.833

4.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

Review 5.  Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines.

Authors:  Danielle M Valcourt; Chintan H Kapadia; Mackenzie A Scully; Megan N Dang; Emily S Day
Journal:  Adv Healthc Mater       Date:  2020-05-04       Impact factor: 9.933

Review 6.  Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.

Authors:  Joon Ho Park; Diana Dehaini; Jiarong Zhou; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Nanoscale Horiz       Date:  2019-06-28       Impact factor: 10.989

7.  Advances in targeted nanotherapeutics: From bioconjugation to biomimicry.

Authors:  Danielle M Valcourt; Jenna Harris; Rachel S Riley; Megan Dang; Jianxin Wang; Emily S Day
Journal:  Nano Res       Date:  2018-05-17       Impact factor: 8.897

Review 8.  Biointerfacing and Applications of Cell Membrane-Coated Nanoparticles.

Authors:  Ashley V Kroll; Ronnie H Fang; Liangfang Zhang
Journal:  Bioconjug Chem       Date:  2016-11-16       Impact factor: 4.774

9.  Reassembly of 89 Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics.

Authors:  Bo Yu; Shreya Goel; Dalong Ni; Paul A Ellison; Cerise M Siamof; Dawei Jiang; Liang Cheng; Lei Kang; Faquan Yu; Zhuang Liu; Todd E Barnhart; Qianjun He; Han Zhang; Weibo Cai
Journal:  Adv Mater       Date:  2018-02-12       Impact factor: 30.849

10.  Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis.

Authors:  Xiaoli Wei; Man Ying; Diana Dehaini; Yuanyuan Su; Ashley V Kroll; Jiarong Zhou; Weiwei Gao; Ronnie H Fang; Shu Chien; Liangfang Zhang
Journal:  ACS Nano       Date:  2017-12-12       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.